Le Dr Robert A. Harrington est cardiologue et occupe le poste de doyen Stephen et Suzanne Weiss de Weill Cornell Medicine ainsi que celui de provost pour les affaires médicales de l'Université Cornell. Ses domaines de recherche se concentrent sur l'évaluation des thérapies antithrombotiques pour traiter les maladies cardiaques ischémiques aiguës, minimiser les complications aiguës des procédures coronariennes percutanées et essayer de mieux comprendre et améliorer la méthodologie de la recherche clinique, notamment l'utilisation des technologies pour faciliter la conduite des essais cliniques. Ancien président de l'American Heart Association (AHA), le Dr Harrington reste membre du conseil d'administration de l'AHA. Il est également membre élu de l'Association of American Physicians, de l'Association of University Cardiologists et de la National Academy of Medicine / Institute of Medicine. De plus, il a été président et membre du Comité consultatif des médicaments cardiovasculaires et rénaux de la Food and Drug Administration (FDA) des États-Unis. Parmi ses nombreuses distinctions et reconnaissances, le Dr Harrington a été nommé Master de l'American College of Cardiology en 2016, a reçu le Clinical Research Prize de l'AHA en 2017 et le Distinguished Achievement Award du Conseil sur la cardiologie clinique (CLCD) de l'AHA en 2022. En 2022, il a reçu la médaille Stokes et, en 2023, la bourse d'honneur de la Irish Cardiac Society. De l'AHA, il a reçu à la fois le Chairman’s Award 2024 et le Gold Award pour son leadership. La Cardiovascular Research Foundation l'a honoré en 2024 avec le TCT (Transcatheter Cardiovascular Therapeutics) Career Achievement Award, en tant qu'individu exceptionnel ayant apporté des contributions extraordinaires au domaine de la cardiologie interventionnelle et ayant eu un impact transformateur sur les soins cardiovasculaires grâce à son excellence clinique, sa recherche pionnière et son mentorat.

Dr. Robert A. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. His research areas of focus include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures and trying to better understand and improve upon the methodology of clinical research, including the use of technologies to facilitate the conduct of clinical trials.  A previous American Heart Association (AHA) president, Dr. Harrington remains a member of AHA’s Board of Directors. He is also an elected member of the Association of American Physicians, the Association of University Cardiologists, and the National Academy of Medicine / Institute of Medicine. In addition, he has served as a chair and member of the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee.  Among his numerous awards and recognition, Dr. Harrington was named a Master of the American College of Cardiology in 2016, was awarded the AHA’s Clinical Research Prize in 2017, and earned the AHA Council on Clinical Cardiology (CLCD) Distinguished Achievement Award in 2022. In 2022, he was awarded the Stokes Medal, and in 2023, Honorary Fellowship in the Irish Cardiac Society. From the AHA he received both the 2024 Chairman’s Award and the Gold Award for his leadership. The Cardiovascular Research Foundation recognized him with the 2024 TCT (Transcatheter Cardiovascular Therapeutics) Career Achievement Award as an outstanding individual who has made extraordinary contributions to the field of interventional cardiology and made a transformative impact on cardiovascular care through clinical excellence, pioneering research and mentorship.